Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of NK Cells From Sibship for Recurrent HCC
NCT02399735Phase 1Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2014
- Primary completion
- Jun 2018
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Natural Killer Cells in hepatocellular carcinoma (HCC) (3 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Graft versus host disease at 6 months. Status: unknown.
02
Drugs
Natural Killer Cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02399735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02399735.